Professor of Cancer Studies
University College London
Presentations at Drug Discovery 2015
Profile of John Hartley
John Hartley is Professor of Cancer Studies in the UCL Cancer Institute and Co-Lead of the UCL Experimental Cancer Medicine Centre. He is also Director of the Cancer Research UK Drug-DNA Interactions Research Group. His research activities are focused around the development of novel cancer therapies, particularly involving DNA as a target.
He obtained a first degree in Biochemistry and a PhD in Oncology, both from Manchester University, and undertook post-doctoral studies at the National Cancer Institute, NIH, USA and the University of Alberta in Canada. He has been at UCL for over 20 years and is a founder of spin-out company Spirogen which was acquired by AstraZeneca in 2013. He continues to be involved at Spirogen as Director of Pre-Clinical Development.
to send a Private Message
The European Laboratory Research & Innovation Group
Our Vision : To provide outstanding, leading edge knowledge to the life sciences community on an open access basis
Get the App
Get this event information on your mobile by
going to the appstore or google play and search for 'elrig